Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin Combined With Chemotherapy in Older Patients With Ph-negative CD22+ BCP-ALL
NCT03249870Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Dec 2017
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Overall Survival at 1 year. Started Dec 2017; status: completed.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03249870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249870.